Publications by authors named "Josh Cone"
Article Synopsis
- Tarperprumig (ALXN1820) is a bispecific antibody designed to treat conditions caused by dysregulated activity in the complement alternative pathway, usable via small volume injections either under the skin or intravenously.
- It consists of two variable domains that target properdin and human serum albumin, showing a high binding affinity and forming a stable complex.
- The antibody effectively inhibits key processes related to complement pathway activation and is currently undergoing clinical development for relevant disorders.
Article Synopsis
- Gefurulimab (ALXN1720) is a bispecific antibody designed for subcutaneous treatment of chronic disorders linked to the activation of the terminal complement pathway by blocking the breakdown of complement component 5 (C5).
- It consists of specialized antibody fragments derived from llamas and humans that bind tightly to C5 and human serum albumin (HSA), enabling it to inhibit complement activity effectively in lab assays.
- Structural studies indicate that gefurulimab obstructs C5's interaction with its activating convertase, suggesting it is a strong candidate for treating complement-mediated disorders.
Article Synopsis
- - This study investigates how immune complexes form when patients are exposed to two different anti-C5 antibodies simultaneously, focusing on the transition from one treatment to another.
- - Researchers used size exclusion chromatography and multiangle light scattering to analyze the interactions between eculizumab and two other anti-C5 antibodies (TPP-2799 and TP-3544), both of which bind C5 similarly.
- - Results showed that when mixed with other antibodies, the complexes formed could exceed 1500 kDa, indicating multiple antibodies and C5 molecules interacting, suggesting the need for careful monitoring and strategies to prevent complex formation during such treatment transitions.
